Atomo Diagnostics (ASX:AT1) obtained an exclusive licensing agreement with the Burnet Institute for its novel rapid Syphilis test assay, carving a path to commercialization for the product, according to a Monday filing with the Australian bourse.
The agreement will enable Atomo to commercialize the test on its Pascal test cassette, the filing stated. Atomo will pay Burnet a royalty fee as a percentage of the net revenue generated by the product.
The agreement is in effect until Burnet's Syphilis patent expires in 2045.
Atomo Diagnostics' shares were up nearly 12% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.